NEW YORK (GenomeWeb) — IMDx said today that it has received three additional licenses for sale and distribution of its molecular tests for the Abbott m2000 platform outside the US and EU.

First, the IMDx C. difficile assay for the qualitative detection of toxigenic Clostridium difficile toxin A and B genes, and the Flu A/B and RSV assay for the qualitative detection of influenza A, influenza B, and respiratory syncytial virus have been approved by Health Canada for sale and distribution in Canada.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.